GoodRx Holdings, Inc.GDRX

GoodRx Holdings reported first-quarter revenue of $194 million and net income of just $1.2 million, producing diluted earnings per share of zero cents. The company's operating income of $14 million and operating cash flow of $11.8 million suggest a business that is profitable on an adjusted basis but barely covering its costs after research and development spending of $30.2 million. The balance sheet shows $2.02 billion in assets against $1.4 billion in liabilities, with cash and equivalents of $235.7 million.

GoodRx operates a prescription drug savings platform in the United States, connecting patients with discounts and coupons for medications. Its revenue comes from pharmacy network fees, subscription plans, and the Pharma Direct segment, which markets drugs directly to consumers. The platform is not available outside the US, limiting its addressable market to domestic patients and pharmacies.

The May 6 press release highlighted subscription revenue growth of 16% to $24.4 million and Pharma Direct revenue growth of 82% to $52.2 million. These segments are driving the top line, but the overall net income remains thin. The company's research and development spending of $30.2 million in the quarter indicates continued investment in technology and platform features, though the return on that spending is not yet visible in net income.

The SEC EDGAR filings include insider transactions from June and July 2026, with multiple Form 4 filings showing executive stock activity. An 8-K filed on June 18 mentions an unspecified corporate event. The diluted share count of 341.4 million shares means any further equity issuance or option exercises will continue to pressure per-share earnings.

What remains unproven is whether GoodRx can translate its revenue growth into sustainable profitability. The operating cash flow is positive but modest, and the company's cash position of $235.7 million provides a buffer but not a moat. A clearer picture would come from the next quarterly filing, which should show whether subscription and Pharma Direct growth rates are accelerating or plateauing, and whether the company can control its R&D and sales costs.